Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | SHBG | P04278 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.70 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | PGR | P06401 | 2/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8217259 | 0.90 | HSD17B10 (0.71) | HSD17B10NR3C1SERPINA6LMNATSHR | |
| SCHEMBL28023466 | 0.90 | HSD17B10 (0.71) | HSD17B10NR3C1SERPINA6LMNATSHR | |
| SCHEMBL342689 | 0.90 | HSD17B10 (0.71) | HSD17B10NR3C1SERPINA6LMNATSHR | |
| SCHEMBL4971575 | 0.90 | HSD17B10 (0.71) | HSD17B10NR3C1SERPINA6LMNATSHR | |
| SCHEMBL5082089 | 0.89 | HSD17B10 (0.70) | HSD17B10NR3C1SERPINA6LMNATSHR | |
| SCHEMBL582662 | 0.88 | FNTA (0.72) | HSD17B10NR3C1SERPINA6LMNATSHR | |
| SCHEMBL28941264 | 0.88 | HSD17B10 (0.69) | HSD17B10NR3C1SERPINA6LMNATSHR | |
| SCHEMBL27607895 | 0.88 | HSD17B10 (0.69) | HSD17B10NR3C1SERPINA6LMNATSHR | |
| SCHEMBL30483614 | 0.87 | HSD17B10 (0.68) | HSD17B10NR3C1SERPINA6LMNATSHR | |
| SCHEMBL21875771 | 0.85 | HSD17B10 (0.66) | HSD17B10NR3C1SERPINA6LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222117-A1 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | PURDUE RESEARCH FOUNDATION | 2025-07-10 | — | — | US | claimed |
| EP-4463149-A2 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | Purdue Research Foundation (US) | 2024-11-20 | — | — | EP | claimed |
| US-12070442-B2 | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | SURFACE OPHTHALMICS, INC. (US) | 2024-08-27 | — | — | US | claimed |
| US-20230331767-A1 | TARGETED STEROID COMPOUNDS | PURDUE RESEARCH FOUNDATION | 2023-10-19 | — | — | US | claimed |
| US-20230277557-A1 | PHARMACEUTICAL KITS AND THEIR USE FOR TREATING DRY EYE DISEASE | SURFACE OPHTHALMICS INC (US) | 2023-09-07 | — | — | US | claimed |
| EP-4214183-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | Essa Pharma, Inc. (CA) | 2023-07-26 | — | — | EP | claimed |
| WO-2023137403-A2 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY | 2023-06-22 | — | — | US | claimed |
| EP-4153299-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | Rodeo Therapeutics Corporation (US) | 2023-03-29 | — | — | EP | claimed |
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | RODEO THERAPEUTICS CORPORATION | 2023-02-09 | — | — | US | claimed |
| US-5192528-A | Encapsulated in liposomes, aerosols | LIPOSOME TECHNOLOGY, INC. (US) | 1993-03-09 | — | — | US | claimed |
| US-5049389-A | Non-phospholipd lipid, delivery by inhalation | LIPOSOME TECHNOLOGY, INC. (US) | 1991-09-17 | — | — | US | claimed |
| US-5043165-A | Cholesterol and salt; antiallergens, antiinflammatory agents, skin disorders | LIPOSOME TECHNOLOGY, INC. (US) | 1991-08-27 | — | — | US | claimed |
| US-4957744-A | COSMETICS, PHARMACEUTICALS, PLASTICS FOR SANITARY AND SURGICAL ARTICLES | FIDIA, S.P.A. (IT) | 1990-09-18 | — | — | US | claimed |
| US-4954345-A | CORTICOSTEROIDS AND-OR TRIHYDROXYANTHRACENES | ROHM PHARMA GMBH (DE) | 1990-09-04 | — | — | US | claimed |
| WO-1990006775-A1 | A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR SUSTAINED RELEASE OF DRUGS | LIPOSOME TECHNOLOGY, INC. (US) | 1990-06-28 | — | — | WO | claimed |
| US-4906476-A | Novel liposome composition for sustained release of steroidal drugs in lungs | LIPOSOME TECHNOLOGY, INC. | 1990-03-06 | — | — | US | claimed |
| US-4851521-A | Esters of hyaluronic acid | FIDIA, S.P.A. (IT) | 1989-07-25 | — | — | US | claimed |
| EP-0265116-A2 | Cross-linked esters of hyaluronic acid | FIDIA S.p.A. (IT) | 1988-04-27 | — | — | EP | claimed |
| EP-0216453-A2 | Esters of hyaluronic acid and their salts. | FIDIA S.p.A. (IT) | 1987-04-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331767-A1 | TARGETED STEROID COMPOUNDS | CYP11B2, FOLR2, CYP11B1 | HSD17B10 131/4885NR3C1 16/4885SERPINA6 24/4885 |
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | HSD17B10 21/4885NR3C1 1540/4885SERPINA6 1375/4885 |
| US-20250222117-A1 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | MTHFD1, MTHFD2, DHFR | HSD17B10 1355/4885NR3C1 1515/4885SERPINA6 1739/4885 |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | HSD17B10 21/4885NR3C1 1540/4885SERPINA6 1375/4885 |
| US-12070442-B2 | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | EYA3, HSD3B1, HMGCR | HSD17B10 749/4885NR3C1 31/4885SERPINA6 25/4885 |
| US-20230277557-A1 | PHARMACEUTICAL KITS AND THEIR USE FOR TREATING DRY EYE DISEASE | TSLP, SERPINA6, IL5 | HSD17B10 1879/4885NR3C1 24/4885SERPINA6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.